Current medical research and opinion
-
This pooled analysis assessed the safety of omalizumab in children with allergic (immunoglobulin E-mediated) asthma. ⋯ Omalizumab has an acceptable safety profile, with a risk of AEs similar to placebo. This, combined with its efficacy profile, suggests that omalizumab may provide an additional asthma management option for children (6 to < 12 years) uncontrolled with current therapy that follows established guidelines.